escitalopram and sertraline — Competitive Intelligence Brief

escitalopram and sertraline (escitalopram and sertraline) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Selective serotonin reuptake inhibitor (SSRI). Area: Psychiatry / Mental Health.

marketed Selective serotonin reuptake inhibitor (SSRI) Serotonin transporter (SERT) Psychiatry / Mental Health Small molecule

Target snapshot

escitalopram and sertraline (escitalopram and sertraline) — Oregon Health and Science University. Both escitalopram and sertraline are selective serotonin reuptake inhibitors (SSRIs) that increase serotonin availability in the brain by blocking its reabsorption at the synaptic cleft.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
escitalopram and sertraline TARGET	escitalopram and sertraline	Oregon Health and Science University	marketed	Selective serotonin reuptake inhibitor (SSRI)	Serotonin transporter (SERT)
Lexapro	escitalopram	Generic (originally Lundbeck/Forest)	marketed	Selective Serotonin Reuptake Inhibitor (SSRI)	Serotonin (5-HT) reuptake transporter	2002-08-14
Prozac	fluoxetine	Eli Lilly and Company	marketed	Selective Serotonin Reuptake Inhibitor (SSRI)	Serotonin reuptake transporter	1987-12-29
Zoloft (antidepressant)	Zoloft (antidepressant)	Unity Health Toronto	marketed	Selective serotonin reuptake inhibitor (SSRI)	Serotonin transporter (SERT)
Paroxetine	paroxetine	Pfizer Inc.	marketed	Selective Serotonin Reuptake Inhibitor (SSRI)	Serotonin (5-HT) reuptake transporter
MDD diagnosis and Fluoxetine treatment	MDD diagnosis and Fluoxetine treatment	University of Pennsylvania	marketed	Selective Serotonin Reuptake Inhibitor (SSRI)	Serotonin Transporter (SERT)
Sertraline [Zoloft]	Sertraline [Zoloft]	Johns Hopkins University	marketed	Selective serotonin reuptake inhibitor (SSRI)	Serotonin transporter (SERT)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Selective serotonin reuptake inhibitor (SSRI) class)

1. University of Texas Southwestern Medical Center · 3 drugs in this class
2. Johns Hopkins University · 2 drugs in this class
3. GlaxoSmithKline · 2 drugs in this class
4. Daiichi Sankyo Co., Ltd. · 1 drug in this class
5. Guangdong Provincial People's Hospital · 1 drug in this class
6. Janssen Research & Development, LLC · 1 drug in this class
7. Medical University of Vienna · 1 drug in this class
8. Massachusetts General Hospital · 1 drug in this class
9. Fundació Sant Joan de Déu · 1 drug in this class
10. Centre Hospitalier Universitaire Dijon · 1 drug in this class